Affordable Access

deepdyve-link
Publisher Website

MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

Authors
  • Iorio, Marilena V1
  • Croce, Carlo M
  • 1 Start Up Unit, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milano, Italy. , (Italy)
Type
Published Article
Journal
EMBO Molecular Medicine
Publisher
EMBO
Publication Date
March 2012
Volume
4
Issue
3
Pages
143–159
Identifiers
DOI: 10.1002/emmm.201100209
PMID: 22351564
Source
Medline
License
Unknown

Abstract

Early studies have shown how aberrantly expressed microRNAs are a hallmark of several diseases like cancer. MicroRNA expression profiling was shown to be associated with tumour development, progression and response to therapy, suggesting their possible use as diagnostic, prognostic and predictive biomarkers. Moreover, based on the increasing number of studies demonstrating that microRNAs can function as potential oncogenes or oncosuppressor genes, with the goal to improve disease response and increase cure rates, miRNA-based anticancer therapies have recently been exploited, either alone or in combination with current targeted therapies. The advantage of using microRNA approaches is based on its ability to concurrently target multiple effectors of pathways involved in cell differentiation, proliferation and survival. Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools.

Report this publication

Statistics

Seen <100 times